Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (256)
Cancellation by sponsor (71)
Prescription medicine registration (25)
Section 14, TGO91 consent (6)
Australian Public Assessment Report (AusPAR) (1)
Prescription medicine decision summary (1)

Date

2024 (11)
2023 (18)
2022 (36)
2021 (70)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (14)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (3)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (5)
1998 (1)
1996 (3)
1994 (3)
1991 (11)

Results for "[search-keyword]"

Search

Sponsor content

360 result(s) found, displaying 201 to 210

MORPHINE JN morphine hydrochloride trihydrate 100 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
MORPHINE JN morphine hydrochloride trihydrate 50 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOMORPH morphine hydrochloride trihydrate 100 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOMORPH morphine hydrochloride trihydrate 20 mg/1 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
MORPHINE JN morphine hydrochloride trihydrate 20 mg/1 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOMORPH morphine hydrochloride trihydrate 50 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
MORPHINE JN morphine hydrochloride trihydrate 10 mg/1 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOMORPH morphine hydrochloride trihydrate 10 mg/1 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 August 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
POSACONAZOLE JUNO, POSCOLE (Juno Pharmaceuticals Pty Ltd)

4 August 2020

Prescription medicine registration

Active ingredients: posaconazole.
ASTRAZENECA SUXAMETHONIUM CHLORIDE 100mg/2mL injection BP ampoule Cancelled under Section 30(1)(c) of the Act

20 July 2020

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 17
Page 18
Page 19
Page 20
Current page 21
Page 22
Page 23
Page 24
Page 25
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.